Additive Manufacturing Strategies

Organovo and Johnson & Johnson Team to Evaluate 3D Bio-printed Tissue Use

ST Medical Devices

Share this Article

It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a org-2functioning liver for transplantation within a human being.

Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.

org-feat

Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. org-1Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.

Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.

What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.

Share this Article


Recent News

NASA Highlights Space 3D Printing Commercialization

Metal 3D Printing Quality Control Systems Developed by Materialise and Sigma Labs



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3DPOD Episode 93: Bound Metal 3D Printing with Mantle CEO Ted Sorom

Ted Sorom, CEO and co-founder of Mantle, is looking to revolutionize metal 3D printing. Mantle has a paste extrusion method that features a post-machining step to mill unfinished parts and...

Featured

Big and Tall Metal 3D Printer Heralds Rocket Future for China’s EPlus 3D

Until recently, Chinese 3D printer manufacturers either stuck to selling in China, made inexpensive 3D printers, made copies of Western printers, or did some combination of all of the above....

Designing and Metal 3D Printing a Dental Implant

Les Kalman is Assistant Professor of Restorative Dentistry and Academic Lead for Continuing Dental Education at Western University’s Schulich School of Medicine & Dentistry. He will be participating in Additive...

3D Printing Webinar and Event Roundup: January 23, 2022

We’ve got plenty of webinars and events to tell you about in this week’s roundup: NAMIC and CASTOR are talking 3D printed parts identification, Carbon has a major announcement, HP...


Shop

View our broad assortment of in house and third party products.